CathNova provides a novel neuromodulation therapy to prevent ventilator-associated pneumonia (VAP), one of the most frequent complications in intensive care units (ICUs). With over two million ventilated patients annually in the US, the VAP prevention therapy represents a SAM (US hospitals) and SOM (ventilation longer than 48 hours) of five and 1.6 billion US dollars, respectively. Intensive care hospitals are highly motivated to adopt effective solutions, as preventing VAP in two third of the cases can save 0.22 lives and costs of $52’700 per year per ICU bed through reduced complications and shorter ICU stays. CathNova’s approach aligns with existing flat tax reimbursement for ICU treatments, facilitating adoption without structural changes to hospital workflows and financing.
